Timothy N. Perkins

Timothy N. Perkins serves as Assistant Professor of Pathology in the Division of Experimental Pathology at the University of Pittsburgh School of Medicine, specializing in molecular mechanisms of obstructive lung diseases. His work addresses chronic respiratory disease—the third leading global cause of death affecting 7.4% of the population—with focus on asthma and COPD pathogenesis.

His academic training includes:

• B.S. in Biological Sciences, University of Vermont (2009)
• M.S. in Microbiology and Molecular Genetics, University of Vermont (2011)
• Ph.D. in Toxicology, Maastricht University, Netherlands (2016)

Dr. Perkins' research centers on RAGE receptor signaling in asthma, investigating how alarmin/DAMP pathways drive heterogeneous disease phenotypes resistant to conventional therapies. His lab employs sophisticated mouse models exhibiting human-relevant features including eosinophilic/neutrophilic inflammation, mucus metaplasia, and airway remodeling. Current projects examine RAGE's role in ozone-induced injury (with NIOSH), respiratory syncytial virus interactions (with Pitt Pharmacy), and pharmaceutical targeting (with Arrowhead).

His publication record demonstrates consistent progression from silica/asbestos toxicology (2012-2018) to specialized RAGE research (2019-present), with recent expansion into environmental triggers and viral exacerbations. This trajectory reflects growing expertise in translating molecular mechanisms to therapeutic development for high-burden respiratory conditions.

While no formal awards are listed, his 2019 Journal of Allergy and Clinical Immunology paper received editorial feature, indicating peer recognition of its significance to the field.

Dr. Perkins maintains active collaborative networks across institutions, suggesting robust grant support. His mentorship likely provides trainees with interdisciplinary experience spanning molecular immunology, environmental health, and pharmaceutical development—preparing students for diverse careers in respiratory research.

Though no dedicated lab name is specified, his research group represents a dynamic hub for investigating fundamental mechanisms of lung disease with direct translational potential for millions suffering from therapy-resistant asthma.